BioCardia, Inc. Files 8-K Report
Ticker: BCDA · Form: 8-K · Filed: Oct 2, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
Related Tickers: BCDA
TL;DR
BioCardia filed an 8-K on Oct 2, 2025, updating its Sunnyvale, CA address.
AI Summary
On October 2, 2025, BioCardia, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 320 Soquel Way, Sunnyvale, California, 94085. The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing serves as an official notification of the company's operational and reporting status with the SEC, providing updated address information.
Risk Assessment
Risk Level: low — This filing is a routine administrative update and does not contain material financial or operational news.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- October 2, 2025 (date) — Date of earliest event reported
- 320 Soquel Way, Sunnyvale, California, 94085 (address) — Principal executive offices
- Securities Exchange Act of 1934 (legal_document) — Governing act for the filing
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information as required by Section 13 or 15(d) of the Securities Exchange Act of 1934, including the company's principal executive offices.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 2, 2025.
What is BioCardia, Inc.'s principal executive office address?
BioCardia, Inc.'s principal executive offices are located at 320 Soquel Way, Sunnyvale, California, 94085.
Under which section of the Securities Exchange Act was this report filed?
This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the state of incorporation for BioCardia, Inc.?
BioCardia, Inc. is incorporated in Delaware.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-10-02 08:00:10
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20251001_8k.htm (8-K) — 26KB
- ex_865820.htm (EX-99.1) — 8KB
- 0001437749-25-030217.txt ( ) — 164KB
- bcda-20251002.xsd (EX-101.SCH) — 3KB
- bcda-20251002_def.xml (EX-101.DEF) — 11KB
- bcda-20251002_lab.xml (EX-101.LAB) — 15KB
- bcda-20251002_pre.xml (EX-101.PRE) — 11KB
- bcda20251001_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 2, 2025, BioCardia, Inc. (the "Company") issued a press release announcing that it received formal written notice from The Nasdaq Stock Market, LLC's Staff that the Company has regained compliance with Listing Rule 5550(b)(1) (the "Equity Rule") of the Nasdaq Stock Market. Accordingly, the Company's common stock will continue to be listed on The Nasdaq Stock Market. A copy of the press release is attached as Exhibit 99.1 to the current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated October 2, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: October 2, 2025